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Open access uand time in therapeutic range (TTR), in patients with nonvalvular atrial ﬁbrillation.
Longitudinal patient-level anticoagulation management records collected from 2006 to 2010
were analyzed. Adult patients with nonvalvular atrial ﬁbrillation who used warfarin for
a 12-month period with no gap of >60 days between visits were identiﬁed. TTR <55% was
deﬁned as “lower” TTR. CHADS2 score of ‡2 was deﬁned as “higher” CHADS2. Logistic
regression analyses were conducted to determine the association between co-morbidities
and TTR. A total of 23,425 patients met the study criteria. The mean age – SD was 74.8 –
9.7 years, with 84.8% aged ‡65 years. The most common co-morbidities were hypertension
(41.7%), diabetes (24.1%), HF (11.7%), and previous stroke (11.1%). The mean TTR – SD
was 67.3 – 14.4%, with 18.6% of patients in the lower TTR range. In multivariate analyses
using age, gender, hypertension, diabetes, stroke, and region as covariates, HF (adjusted
odds ratio [OR] 1.41, 95% conﬁdence interval [CI] 1.28 to 1.56; p <0.001), diabetes
(OR 1.28, 95% CI 1.19 to 1.38; p <0.001), and previous stroke (OR 1.15, 95% CI 1.04 to
1.27; p <0.001) were associated with lower TTR. In a second set of multivariate analyses
using gender and region as covariates, a higher CHADS2 score was associated with lower
TTR (OR 1.11, 95% CI 1.04 to 1.18; p <0.001). In conclusion, HF was associated with the
greatest likelihood of a lower TTR, followed by diabetes, then stroke. Anticoagulation
control may be more challenging for patients with these conditions. 2013 The Authors. Published by Elsevier Inc. (Am J CarOpen access under CC BY license. -clinics in the United States.diol 2013;112:509 512)e
Until recently, vitamin K antagonists such as warfarin
were the only efﬁcacious oral anticoagulants available for
the prevention of embolic events in patients with non-
valvular atrial ﬁbrillation (NVAF) at high risk of stroke.1,2
For most patients on long-term warfarin therapy, an inter-
national normalized ratio (INR) of 2.0 to 3.0 is the recom-
mended range for prevention of stroke and systemic
embolism3; this level of anticoagulation has been shown to
translate to improved outcomes in patients with NVAF.4,5
Time spent in therapeutic range (TTR), a measure used to
describe the quality of INR control in clinical practice, alsoth improved patient outcomes.6,7 Thus,
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nder CC BY license.characterizing TTR and the variables that can inﬂuence it,
may be helpful in identifying challenges to optimal anti-
coagulation and improving anticoagulation strategies. The
present analysis sought to determine the association among
co-morbidities, patient characteristics, and TTR in patients
with NVAF whose INR was managed by anticoagulationMethods
This study used longitudinal patient-level anticoagulation
management records collected from 2006 to 2010 by the
decision support software CoagClinic (Standing Stone, Inc.,
Westport, Connecticut). This software is used by a large
number of institutions (mostly hospital-based) in 49
states. As of December 2010, this system contained data
onw400,000 patients; this is the largest database of patients
receiving anticoagulation therapy.
Because the data were intended to be used for clinical
purposes, the International Classiﬁcation of Diseases 9th
Revision, Clinical Modiﬁcation codes used for medical
claims were not included. Therefore, all the data ﬁelds were
converted into International Classiﬁcation of Diseases 9th
Revision, Clinical Modiﬁcation format to extract co-
morbidity information.
Adult patients with NVAF who used warfarin for1 year
with no gap of>60 days between anticoagulation clinic visitswww.ajconline.org
Table 1
Patient demographic and baseline characteristics
Characteristic Total, n ¼ 23,425 (%)
Age (yrs)
18 to <65 3,572 (15.3)
65 to <75 6,432 (27.5)
75 13,421 (57.3)
Women 10,864 (46.4)
Men 12,556 (53.6)
CHADS2 score
0 3,890 (16.6)
1 8,736 (37.3)
2 6,403 (27.3)
3 2,841 (12.1)
4 1,154 (4.9)
5 346 (1.5)
6 55 (0.2)
Co-morbidities
Heart failure 2,733 (11.7)
Hypertension 9,765 (41.7)
Diabetes mellitus 5,636 (24.1)
Previous stroke 2,593 (11.1)
United States region
Northeast 6,447 (27.5)
Midwest 6,673 (28.5)
West 4,385 (18.7)
South 4,965 (21.2)
Table 2
Impact of demographics and co-morbidities on likelihood of lower time in
therapeutic range
Characteristic OR (95% CI) p
Age 75 (vs <75) (yrs) 0.94 (0.88e1.01) NS
Men (vs women) 0.78 (0.73e0.83) <0.001
United States region
Northeast 1.00 (Referent) —
West 1.39 (1.26e1.54) <0.001
South 1.38 (1.26e1.52) <0.001
Midwest 1.04 (0.95e1.14) NS
Co-morbidities (vs not present)
Heart failure 1.41 (1.28e1.56) <0.001
Diabetes 1.28 (1.19e1.38) <0.001
Previous stroke 1.15 (1.04e1.27) 0.0075
Hypertension 0.86 (0.80e0.93) <0.001
CI ¼ conﬁdence interval; OR ¼ odds ratio.
Figure 1. The relation between TTR and CHADS2 score (0 to 6).
Table 3
Impact of CHADS2 score on likelihood of lower time in therapeutic range
Characteristic OR (95% CI) p
CHADS2 score 2 (vs <2) 1.11 (1.04e1.18) 0.003
Men (vs women) 0.80 (0.75e0.85) <0.001
United States region
Northeast 1.00 (Referent) —
West 1.43 (1.29e1.58) <0.001
South 1.39 (1.27e1.53) <0.001
Midwest 1.06 (0.96e1.16) NS
CI ¼ conﬁdence interval; OR ¼ odds ratio.
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Figure 2. Sensitivity analysis of the relation between CHADS2 score and
TTR cut-off point used to deﬁne lower range. Analyses were performed for
6 different TTR cut-off points: 45%, 50%, 55%, 60%, 65%, and 70%.
These cut-off points deﬁned high and low TTR values. Adjusted odds ratios
(ORs) >1 indicate that a CHADS2 score 2 was associated with lower
TTR. The adjusted ORs are statistically signiﬁcant when the 95% conﬁ-
dence intervals (CIs) exclude 1.
510 The American Journal of Cardiology (www.ajconline.org)were identiﬁed; this criterion is in alignment with standard
clinical practice, in which regular weekly, bimonthly, or
monthly visits are recommended. Subjectswith valvular atrial
ﬁbrillation were excluded. TTR was calculated according to
the Rosendaal method, which uses linear interpolation to
assign an INR value to each day between successive observed
INR values.8 This approach, which assumes that INR is
gradually increasing or decreasing between measurements,
will produce a percentage of days when the INR measure-
ments are within a prespeciﬁed range. TTRwas calculated for
interpolated INR values within the recommended therapeutic
range of 2.0 to 3.0.
Two sets of independent logistic regression analyses
were conducted. The ﬁrst set was conducted to determine
the association between TTR and co-morbidities, includingheart failure (HF), hypertension, diabetes, and previous
stroke. “Lower” TTR was deﬁned as <55%. The second set
was conducted to determine the association between TTR
and CHADS2 score—a cumulative point-based scoring
system. We used CHADS2 scoring rather than CHA2DS2-
VASc, as it is more widely used in the United States despite
CHA2DS2-VASc being more inclusive in Europe, and it is
stipulated as the primary approach for stratifying stroke risk
Arrhythmias and Conduction Disturbances/Impact of Co-morbidities on TTR 511in patients with NVAF in the most current American
College of Chest Physicians guidelines.9
The CHADS2 system assigns 1 point for each of the
following: presence of HF, presence of hypertension, age
75 years, and presence of diabetes. Two points are
assigned for a history of stroke or a transient ischemic
attack. In the present study, a “higher” CHADS2 score was
deﬁned as 2.
Sensitivity analyses were conducted using TTR cut-off
points at 45%, 50%, 55%, 60%, 65%, and 70% to determine
the impact of different deﬁnitions of low and high TTR on
the relation between CHADS2 scores and TTR.
Results
A total of 23,425 patients met the study criteria. Patients
had a mean age of 74.8  9.7 years, with 84.8% aged 65
years. More than 1/2 (53.9%) of patients had a CHADS2
score <2. Patient demographics are listed in Table 1.
The most common co-morbidities were hypertension,
diabetes, HF, and previous stroke. The mean TTR  SD
was 67.3  14.4%, with 18.6% of patients in the lower TTR
range. Using age, gender, hypertension, diabetes, stroke,
and region as covariates, multivariate analysis (Table 2)
revealed that increased risk for having a lower TTR was
signiﬁcantly and independently associated with HF, dia-
betes, and previous stroke. Patients in the Western and
Southern regions of the United States were signiﬁcantly
more likely to have lower TTR values than those in the
Northeast region (Table 2). Male patients had a lower
likelihood of having a lower TTR (Table 2); conversely,
female patients were at an increased risk for having lower
TTR values. Neither older age (75 years) nor location in
the Midwest (as compared with the Northeast) was inde-
pendently associated with the likelihood of lower TTR in
this analysis.
A negative correlation between CHADS2 scores and
TTR is shown in Figure 1; the highest CHADS2 score, 6,
was associated with the lowest TTR. In the second multi-
variate analysis using gender and region as covariates
(Table 3), a higher CHADS2 score, deﬁned as 2, was
signiﬁcantly associated with a lower TTR. As in the ﬁrst
multivariate analysis, patients in the Western and Southern
regions of the United States were signiﬁcantly more likely to
have lower TTR values than those in the Northeast region
(Table 3). Male patients also continued to have a lower
likelihood of having a lower TTR compared with female
patients (Table 3).
Sensitivity analyses on the impact of different deﬁnitions
of low and high TTR on the relation between CHADS2
scores and TTR found the results of our analysis to be
consistent. Depending on the TTR cut-off points used to
deﬁne lower TTR, estimates of the odds ratio of higher
CHADS2 associated with lower TTR ranged from 1.1 to
1.16 (Figure 2).
Discussion
Although TTR is routinely assessed, there is a lack of
a consensus on an acceptable TTR. For the purpose of our
analysis, the cut-off point for TTR was deﬁned as 55%
in alignment with the meta-analysis by Baker et al.7 By thisdeﬁnition, approximately 19% of patients included in the
analysis were found to have a lower TTR. Patients with
a higher CHADS2 score and co-morbidities—speciﬁcally,
diabetes, stroke, and HF—were more likely to have a lower
TTR. We may hypothesize that a lower TTR found in
patients with co-morbidities, such as diabetes, could be
associated with concomitant chronic kidney disease, which
is known to reduce anticoagulation stability.10
This analysis supports observations from previous
research.6,11e16 In a retrospective cross-sectional study of
patients with atrial ﬁbrillation in Israel treated with warfarin
for 6 months, HF and female gender were signiﬁcant
predictors of low TTR, deﬁned as TTR <60%.11 Moreover,
diabetes and stroke were also signiﬁcantly associated with
lower TTR. Interestingly, patients with excellent anti-
coagulation control (deﬁned as TTR >75%) were less likely
to have these co-morbidities. Substantial co-morbidities
(39% had diabetes and 31% had HF) were also found in
patients with low TTR in 100 United States Veteran Affairs
sites; patients from these sites, adjusted for the lowest
predicted TTR, had several-fold higher rates of co-morbid-
ities compared with patients from sites with the highest
predicted TTR.17
Conﬂicting results exist regarding age and its association
with anticoagulation control. The Cardiovascular Research
Network WAVE (Warfarin for AF or VTE) analysis found
that age >50 years was a predictor of not having a low TTR,
and the retrospective study in Israel found older age to be
associated with a lower TTR,11,18 whereas our study found
no age association. We hypothesize that the lack of age
association in our study is a consequence of stricter adher-
ence to the anticoagulation regimen among older compared
with younger patients, as a result of their greater experi-
ence in taking medicines. Younger patients also tend to
perceive themselves as healthier and thus may be less likely
to adhere to their medication regimen. To further quantify
our ﬁndings of no age association, we recomputed the
primary logistic regression model with age as a continuous
variable instead of a dichotomized variable. The odds ratios
of the co-morbidities did not change, and no statistical or
clinical signiﬁcance was found between TTR and increasing
age. The use of the secondary model was thus omitted
from the ﬁnal analyses. Given the high prevalence of
co-morbidities in patients with NVAF, their potential asso-
ciation with lower TTR is of note. In this study, HF was
associated with the greatest likelihood of a lower TTR,
followed by diabetes, then previous stroke. Anticoagulation
control may be more challenging for patients with these
co-morbidities; therefore, strategies should be undertaken by
the clinician to improve TTR in these patients. Because the
patients in our study attended anticoagulation clinics regu-
larly and received specialized care, we believe that lower
TTR was not a consequence of a lack of strict INR control.
We therefore hypothesize that for such complex patients,
adjusting the anticoagulation regimen, for example by
implementing novel oral anticoagulant agents, might
improve the quality of anticoagulation care.
The limitations of our study include its retrospective
observational nature and potentially incomplete data records,
whichmay fail to report preexisting co-morbidities ormay not
be generalized to patients managed in settings other than
512 The American Journal of Cardiology (www.ajconline.org)anticoagulation clinics. In this analysis, any misclassiﬁcation
would most likely reﬂect unreported co-morbidities, that is
a patient with a co-morbidity being classiﬁed as not having
one. Underreporting would bias our odds ratio ﬁndings
toward the null hypothesis; thus, our ﬁndings may be more
conservative than the true value. Other factors that may
contribute to lower TTR, such as adherence to prescribed
anticoagulant regimens, were not evaluated, because the
information was not included in the database.
In summary, common co-morbidities that accompany
NVAF are associated with lower TTR. HF is associated
with the greatest likelihood of a lower TTR, followed by
diabetes, then previous stroke. Anticoagulation control may
be more challenging for patients with these conditions. As a
result, clinicians should pay special attention to patients with
NVAF who have co-morbid conditions.
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